Engineered immune cells take on Hard-to-Treat cancers
NCT ID NCT07179692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors like lung, stomach, colon, rectal, esophageal, or pancreatic cancer that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry a protein called CEA. The main goals are to check safety and find the best dose, while also seeing if it can control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 901 Hospital of Joint Logistics Support Force of People Liberation Army
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can we predict who will survive a bowel surgery leak?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?